Protalix BioTherapeutics, Inc.
PLX
$2.22
-$0.14-5.93%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 80.62M | 76.38M | 52.74M | 61.84M | 61.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.62M | 76.38M | 52.74M | 61.84M | 61.95M |
| Cost of Revenue | 43.72M | 41.83M | 45.88M | 38.64M | 38.69M |
| Gross Profit | 36.90M | 34.55M | 6.86M | 23.20M | 23.26M |
| SG&A Expenses | 12.62M | 12.13M | 11.68M | 11.16M | 10.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.33M | 56.59M | 58.24M | 55.47M | 53.72M |
| Operating Income | 23.29M | 19.79M | -5.50M | 6.37M | 8.23M |
| Income Before Tax | 23.46M | 19.27M | -5.61M | 6.48M | 8.09M |
| Income Tax Expenses | 4.52M | 3.93M | 996.00K | 1.09M | 1.81M |
| Earnings from Continuing Operations | 18.95 | 15.33 | -6.60 | 5.39 | 6.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.95M | 15.33M | -6.60M | 5.39M | 6.28M |
| EBIT | 23.29M | 19.79M | -5.50M | 6.37M | 8.23M |
| EBITDA | 24.86M | 21.31M | -4.04M | 7.78M | 9.60M |
| EPS Basic | 0.24 | 0.19 | -0.08 | 0.08 | 0.09 |
| Normalized Basic EPS | 0.18 | 0.15 | -0.04 | 0.06 | 0.07 |
| EPS Diluted | 0.23 | 0.18 | -0.09 | 0.05 | 0.05 |
| Normalized Diluted EPS | 0.18 | 0.14 | -0.05 | 0.04 | 0.05 |
| Average Basic Shares Outstanding | 318.63M | 317.30M | 314.07M | 304.78M | 299.05M |
| Average Diluted Shares Outstanding | 325.93M | 324.64M | 318.21M | 343.02M | 343.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |